• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性肿瘤中的抗磷脂抗体:这些是致病的还是偶然现象?

Antiphospholipid antibodies in malignancy: are these pathogenic or epiphenomena?

机构信息

Department of Medicine, University of California, Irvine, CA, USA.

出版信息

J Clin Rheumatol. 2011 Dec;17(8):429-31. doi: 10.1097/RHU.0b013e31823b0ca5.

DOI:10.1097/RHU.0b013e31823b0ca5
PMID:22089988
Abstract

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial and venous thrombotic events associated with antiphospholipid antibodies. Antiphospholipid syndrome is commonly seen with collagen vascular diseases; however, other entities that can cause APS include chronic viral infections, certain medications, and malignancies. We present an interesting patient with an atypical presentation and course of presumed APS, which lead us to perform an exhaustive search for a secondary cause. The patient was ultimately found to have splenic marginal zone lymphoma. Analysis of the current data in the literature is presented for APS, antiphospholipid antibodies, and malignancy. Based on the literature findings and our experience, we recommend a thorough and repeated evaluation for an underlying malignancy in patients who have an atypical presentation and features of APS.

摘要

抗磷脂综合征(APS)是一种自身免疫性疾病,其特征是存在抗磷脂抗体相关的动脉和静脉血栓事件。APS 常见于胶原血管疾病;然而,其他可能导致 APS 的实体包括慢性病毒感染、某些药物和恶性肿瘤。我们呈现了一位具有非典型表现和疑似 APS 病程的有趣患者,这促使我们进行了详尽的继发性病因搜索。最终发现该患者患有脾边缘区淋巴瘤。本文呈现了 APS、抗磷脂抗体和恶性肿瘤的当前文献数据的分析。根据文献研究结果和我们的经验,我们建议对具有非典型表现和 APS 特征的患者进行彻底和重复的潜在恶性肿瘤评估。

相似文献

1
Antiphospholipid antibodies in malignancy: are these pathogenic or epiphenomena?恶性肿瘤中的抗磷脂抗体:这些是致病的还是偶然现象?
J Clin Rheumatol. 2011 Dec;17(8):429-31. doi: 10.1097/RHU.0b013e31823b0ca5.
2
Antiphospholipid antibodies and renal involvement.抗磷脂抗体与肾脏受累。
Am J Nephrol. 2009;30(5):405-12. doi: 10.1159/000235941. Epub 2009 Aug 28.
3
[Primary antiphospholipid syndrome].[原发性抗磷脂综合征]
Oftalmologia. 2008;52(1):13-7.
4
[Antiphospholipid antibodies and cancer].[抗磷脂抗体与癌症]
Pathol Biol (Paris). 2008 Jun;56(4):245-50. doi: 10.1016/j.patbio.2008.02.012. Epub 2008 May 5.
5
Antiphospholipid antibody syndrome. A literature review.抗磷脂抗体综合征。文献综述。
Minn Med. 2001 Apr;84(4):42-6.
6
Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').抗磷脂综合征(APS)有和无抗磷脂抗体(所谓的“血清阴性 APS”)的临床表现。
Ann Rheum Dis. 2012 Feb;71(2):242-4. doi: 10.1136/annrheumdis-2011-200614. Epub 2011 Sep 27.
7
Case records of the Massachusetts General Hospital. Case 39-2008. A 51-year-old woman with splenomegaly and anemia.马萨诸塞州总医院病例记录。病例39 - 2008。一名患有脾肿大和贫血的51岁女性。
N Engl J Med. 2008 Dec 18;359(25):2707-18. doi: 10.1056/NEJMcpc0806981.
8
Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature.利妥昔单抗对抗磷脂综合征临床及实验室特征的影响:1例病例报告及文献综述
Lupus. 2008 Jan;17(1):50-5. doi: 10.1177/0961203307085251.
9
The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.IgA抗磷脂检测在系统性红斑狼疮抗磷脂(休斯)综合征诊断中的价值。
J Rheumatol. 2001 Dec;28(12):2637-43.
10
The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies.抗β2-糖蛋白 I 抗体在有或无抗磷脂综合征患者中的亲和力:在欧洲抗磷脂抗体论坛框架内的合作研究。
Lupus. 2011 Oct;20(11):1166-71. doi: 10.1177/0961203311406308. Epub 2011 Jun 28.

引用本文的文献

1
Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.通过血清蛋白质组分析确定的胆管癌患者血清中的自身抗体特征。
J Transl Med. 2016 Jan 16;14:17. doi: 10.1186/s12967-015-0751-2.